OUTLOOK THERAPEUTICS INC

Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of LYTENAVA (bevacizumab-vikg in the U.S., bevacizumab gamma in the EU/UK), the only ophthalmic formulation of bevacizumab approved by the U.S. FDA and authorized by the European Commission and UK MHRA for the treatment of wet age-related macular degeneration (wet AMD). The company is preparing for a U.S. commercial launch of LYTENAVA planned before the end of calendar 2026 and has commenced commercial launch in Germany, Austria, and the United Kingdom. LYTENAVA targets the anti-VEGF therapy market, which represents the standard of care for millions of patients with retinal diseases worldwide. Bevacizumab is already widely used off-label in the wet AMD market, and LYTENAVA addresses the longstanding need for an FDA-approved ophthalmic formulation. The company is building a commercial infrastructure including payer engagement, reimbursement support, and a focused sales organization targeting retina practices. Updated Aug 14, 2026